

USSN Not yet assigned
BUNDSCHUH, et al.
Page 1 of 5

Appendix A

Claim Amendments

1. (Currently amended) ~~Pharmaceutical~~ A pharmaceutical composition suited for administration by inhalation, which comprises roflumilast and an anticholinergic agent selected from the group consisting of ipratropium, oxitropium and tiotropium salts together with a pharmaceutically acceptable excipient and/or carrier ~~excipients and/or carriers~~ in a fixed or free combination.
2. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 1, which is a fixed combination.
3. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 1, which is a free combination.
4. (Currently amended) [[A]] The pharmaceutical composition according to claim 1, ~~2 or 3~~ wherein the anticholinergic agent is tiotropium bromide or tiotropium bromide monohydrate.

USSN Not yet assigned
BUNDSCHUH, et al.
Page 2 of 5

5. (Currently amended) ~~[[A]]~~ The pharmaceutical composition according to claim 1, ~~2-or-3~~ wherein the anticholinergic agent is ipratropium bromide.

6. (Currently amended) ~~[[A]]~~ The pharmaceutical composition according to claim 1, ~~2-or-3~~, wherein the anticholinergic agent is oxitropium bromide.

7. (Currently amended) ~~[[A]]~~ The pharmaceutical composition according to claim 1 ~~any of claims 1 to 6~~, wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide.

8. (Currently amended) ~~[[A]]~~ The pharmaceutical composition according to claim 1 ~~any of claims 1 to 6~~, wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxypyrid-4-yl)benzamide.

9. (Currently amended) ~~Method~~ A method for preventing or reducing the onset of symptoms of a respiratory disease, or treating or reducing the severity of a respiratory disease by administering to a patient in need thereof by inhalation

USSN Not yet assigned
BUNDSCHUH, et al.
Page 3 of 5

an effective amount of roflumilast and an anticholinergic agent selected from the group consisting of ipratropium, oxitropium and tiotropium salts, either in a single combined form, separately, or separately and sequentially, where the sequential administration is close in time or remote in time.

10. (Currently amended) ~~Method~~ The method according to claim 9, wherein the anticholinergic agent is tiotropium bromide or tiotropium bromide monohydrate.

11. (Currently amended) ~~Method~~ The method according to claim 9, wherein the anticholinergic agent is ipratropium bromide.

12. (Currently amended) ~~Method~~ The method according to claim 9, wherein the anticholinergic agent is oxitropium bromide.

13. (Currently amended) ~~Method~~ The method according to claim 9 ~~any of claims 9 to 12~~, wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide.

USSN Not yet assigned
BUNDSCHUH, et al.
Page 4 of 5

14. (Currently amended) ~~Method~~ The method according to claim 9 ~~any of claims 9 to 12~~, wherein roflumilast represents 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloro-1-oxypyrid-4-yl)benzamide.

15. (Currently amended) ~~Method~~ The method according to claim 9 ~~any of claims 9 to 14~~, wherein the respiratory disease is COPD.

16-22. (Canceled)

23. (New) The pharmaceutical composition according to claim 2, wherein the anticholinergic agent is tiotropium bromide or tiotropium bromide monohydrate.

24. (New) The pharmaceutical composition according to claim 2, wherein the anticholinergic agent is ipratropium bromide.

25. (New) The pharmaceutical composition according to claim 2, wherein the anticholinergic agent is oxitropium bromide.

USSN Not yet assigned
BUNDSCHUH, et al.
Page 5 of 5

26. (New) The pharmaceutical composition according to claim 3, wherein the anticholinergic agent is tiotropium bromide or tiotropium bromide monohydrate.

27. (New) The pharmaceutical composition according to claim 3, wherein the anticholinergic agent is ipratropium bromide.

28. (New) The pharmaceutical composition according to claim 3, wherein the anticholinergic agent is oxitropium bromide.